Wednesday, July 31, 2013

Family Members Siblings Getting Along to Care for Aging Parents ...

Keep in mind that you'll be judged for your caregiving choices for decades after a parent eventually dies: No brother or sister will ever forget who was there in Mom's hour of need ? and who else was too busy pursuing his own career, or raising her own kids or grandkids, to pitch in. Memories like these have the weight and permanence of chiseled stone.

Beware of reversion

My brother and I can attest to the fact that caring for an aging parent revives childhood rivalries. Siblings may find themselves jockeying for decision-making power, or maneuvering to become a parent's favorite. Remind yourself that you are all adults now ? no need to revive the relationship patterns of your early family life. Reason and mutual respect are the best ways to achieve liberation from the past, as well as to safeguard a parent's future.

Shelve the sexism

All this applies likewise to gender roles. Too often, brothers expect their sisters to bear the brunt of caregiving; after all, didn't females do more family-oriented work (such as household chores) when they were all growing up together? But what woman would not fume at a brother who shirks his caregiving responsibilities today? Only when gender expectations are set aside can siblings become effective partners.

Equality is unrealistic ? and possibly inefficient

Few groups of siblings achieve a perfect division of caregiving duties: For reasons having to do with time, resources, proximity and personality, one or more almost always winds up taking more initiative than the others. This may, in fact, be a better way for the group to decide quickly and act fast. What's important is that every sibling be allowed to contribute in some way. Think about holding quarterly meetings to fine-tune the caregiving plan; this builds a more cohesive team and gives you a forum where you can acknowledge each sibling's contributions.

Be kind to one another

Caregiving is frustrating; not every aging parent is cooperative or appreciative, and some are downright rude. Caregiving tasks can be unpleasant, testing the patience of even the most devoted offspring. It's OK for siblings to vent their frustrations to one another ? so long as it goes no further than that! Recognize that this is hard work, and treat your caregiving partners with empathy.

Advice is easy to give but hard to implement

I'm still trying to apply the counsel above in my relationship with my brother. The mutual respect is there ? we've both acknowledged we make sizable sacrifices on Mom's behalf ? and the kindness is slowly returning. We have more work to do, but at least we know we are tackling it.

Clinical psychologist and family therapist Barry J. Jacobs writes regularly about caregiving issues for AARP. He is the author of The Emotional Survival Guide for Caregivers: Looking After Yourself and Your Family While Helping an Aging Parent.

Source: http://www.aarp.org/home-family/caregiving/info-07-2013/family-siblings-aging-parents-jacobs.html

madmen james cameron liam hemsworth miss canada justin bieber boyfriend marianas trench camille grammer

Justin Timberlake Takes Fans On Fantastic Voyage In 'Take Back The Night' Video

Clip will debut on Tuesday with interactive behind-the-scenes content on Twitter.
By Gil Kaufman

Source: http://www.mtv.com/news/articles/1711391/justin-timberlake-take-back-night-music-video-interactive.jhtml

www.walmart.com Macho Camacho Rise of the Guardians Pumpkin Pie Jack Taylor Apple Pie Recipe black friday

Tuesday, July 30, 2013

Kolberg Crowned NewsChannel 7 Golf Classic Champ

').addClass('pl-'+video.id).append(
$('').append(''+video.title+'').find('a').click(function() { if($(document).data('first')) { $(document).data('second', true); } var ts = Math.round((new Date()).getTime() / 1000); g_anvato_objects['playlistembed'].config.dfp = {adtag:'http://pubads.g.doubleclick.net/gampad/ads?sz=640x480&iu=/301721715/WSAW&ciu_szs&impl=s&gdfp_req=1&env=vp&output=xml_vast2&ad_rule=1&unviewed_position_start=1&correlator='+ts+'&cmsid=3515&vid=ANV_GRTV_'+video.id}; g_anvato_objects['playlistembed'].config.canonical_url="http://www.wsaw.com/video?videoid="+video.id; g_anvato_objects['playlistembed'].loadVideo(video.id,53, 'GRTV'); $('.playlist_list').removeClass('current'); $('.pl-'+video.id).addClass('current'); $('.rec-'+video.id).addClass('current'); }) ) ); } else { var ts = Math.round((new Date()).getTime() / 1000); g_anvato_objects['playlistembed'].config.dfp = {adtag:'http://pubads.g.doubleclick.net/gampad/ads?sz=640x480&iu=/301721715/WSAW&ciu_szs&impl=s&gdfp_req=1&env=vp&output=xml_vast2&ad_rule=1&unviewed_position_start=1&correlator='+ts+'&cmsid=3515&vid=ANV_GRTV_'+initVideo}; g_anvato_objects['playlistembed'].config.canonical_url="http://www.wsaw.com/video?videoid="+video.id; g_anvato_objects['playlistembed'].loadVideo(video.id,53, 'GRTV'); $('#playlist').addClass('hidePlaylist'); }; }; }); $('.pl-'+id+' a').click(); $(document).data('first', true); var ts = Math.round((new Date()).getTime() / 1000); g_anvato_objects['playlistembed'].config.dfp = {adtag:'http://pubads.g.doubleclick.net/gampad/ads?sz=640x480&iu=/301721715/WSAW&ciu_szs&impl=s&gdfp_req=1&env=vp&output=xml_vast2&ad_rule=1&unviewed_position_start=1&correlator='+ts+'&cmsid=3515&vid=ANV_GRTV_'+initVideo}; g_anvato_objects['playlistembed'].config.canonical_url="http://www.wsaw.com/video?videoid="+initVideo; g_anvato_objects['playlistembed'].loadVideo(initVideo,53, 'GRTV'); $('.playlist_list').removeClass('current'); $('.pl-'+initVideo).addClass('current'); $('.rec-'+initVideo).addClass('current'); } function load_tabbed_playlist(data) { var videos = data.videos; var id = ''; $('#tabbed_playlist').html(''); jQuery.each( videos, function(key, video) { if (key == 0) id = video.id; $('#tabbed_playlist').append( $('').addClass('pl-'+video.id).addClass('row-fluid').attr('style', 'padding-bottom:4px; margin:0px;').append( $('').append( $('').append( '' ).find('a').click(function() { if($(document).data('first')) { $(document).data('second', true); } g_anvato_objects['tabbedplayerembed'].loadVideo(video.id, 53, 'GRTV'); $('.playlist_item').removeClass('current'); $('.pl-'+video.id).addClass('current'); $('.rec-'+video.id).addClass('current'); }).append( $('').attr('src', video.thumbnail).attr('height', '55px') ) ), $('').append( $('').append( $('').text(video.title) ) ) ) ) }); $('#tabbed-vod-player').attr('style', ''); $('#tabbed-vod-player').removeClass(); $('.pl-'+id+' a').click(); $(document).data('first', true); } function change_video(vidid,playerid,mcpid) { g_anvato_objects['playerembed'].loadVideo(vidid,playerid,mcpid); }

The 53rd edition of the NewsChannel 7 Golf Classic is in the books, with history being made in both The Classic and Senior Men's at Bass Lake Golf Course.

Kyle Kolberg of Indianhead G.C. took home The Classic title, shooting a 72 on Sunday, 142 for the tournament. Kolberg began Sunday six shots back of first round leader Brian Krueger from Riverdale G.C. Kolberg won by three shots and his six-shot come from behind victory was the largest in tournament history.

Krueger had a tournament record setting 66 on Saturday giving him a three shot lead heading into Sunday's final day, but a day two 79 sent him to his fourth career runner-up finish.

This year's tournament also featured two hole-in-ones.

Jim Teymer from Eagle River G.C. shot the Classic's ninth hole-in-one on Saturday, the first since 1996.

2011 Senior champ Mark Heiting of Greenwood Hills C.C. followed up with the second hole-in-one in as many days and tenth in Classic history on Sunday.

Both were shot on the eighth hole.

In the Senior Men's, Joe Mertens of Greenwood Hills C.C. was crowned champion on Friday, edging out defending champ from Bullseye C.C. Rick Miller by one stroke. Miller double bogeyed 16 on Friday, and Mertens calmly sank a 12-foot par put on 18 to clinch his first career championship.

On Friday, the players had to endure two rain delays that totaled more than two hours. Saturday and Sunday was unseasonably cool and damp, but play was never halted during The Classic.

Source: http://www.wsaw.com/home/headlines/Holberg-Crowned-NewsChannel-7-Golf-Classic-Champ-217329711.html

Michael Strahan Griselda Blanco Michelle Obama Speech Michael Clarke Duncan Nazanin Boniadi Deval Patrick Dedication 4

Video: Preventing military suicides with civilian help

AP Video

Published

Last updated

As the number of veterans committing suicide has climbed to an alarming rate, a civilian-run treatment center has now become a model for treating PTSD and other causes of military suicides.

?

Source: http://www.theglobeandmail.com/news/news-video/video-preventing-military-suicides-with-civilian-help/article13476429/?cmpid=rss1

Daily Caller Staten Island Trick or Treat Amy Weber Happy Halloween! Star Wars Episode 7 jfk airport

Can NBA players fix sports?

Updated?Jul 29, 2013 8:50 PM ET

?

In an effort to lift itself from the dysfunction and ineffectiveness of the Billy Hunter-Derek Fisher regime, the NBA players association has spent the past month identifying four candidates to succeed Hunter as executive director.

Led by 18-year veteran Jerry Stackhouse, the NBPA has narrowed its options to former NBA coach and league executive Stu Jackson, Pistons legend and former NBA coach Isiah Thomas, former Madison Square Garden executive Steve Mills and Charlotte Bobcats president Fred Whitfield, FOXSports.com has learned. Sports attorney David Cornwell is said to be a longshot candidate.

?I?m totally denying we are down to those four prospects,? Stackhouse told me Sunday afternoon. ?Those are just four well-known guys, guys who know our business, guys who have ideas we wanted to hear from. They are not the only guys we want the search firm to vet. I haven?t even had a chance to talk with Fred Whitfield yet. I was planning to do that on Monday.?

Stackhouse said the timetable for the union to name an executive director is between Christmas and NBA All-Star Weekend. He said the union needed to first clean up its bylaws and structure.

?Our long-term deadline is to have our guy in place around the same time as when Adam (Silver) replaces David Stern,? Stackhouse said. ?We want our guy in place to begin the process of forging a relationship with Adam.?

Mills, who runs a financial planning company for athletes and entertainers, has been considered the front-runner ever since Hunter was ousted in February. Like Stu Jackson, Mills has a strong rapport with deputy commissioner Adam Silver, who will replace David Stern as commissioner midway through the upcoming season.

Regardless of who gets the job, it?s clear the NBA and the NBPA want to usher in a spirit of cooperation and shared goals that were missing during the Stern-Hunter era. Stern and Hunter feuded. Hunter fell into the media-laid trap of believing his only job was to engage Stern in a racially tinged war over the collective bargaining agreement.

Silver and the new executive director will likely embrace the Gene Upshaw-Paul Tagliabue-NFL model. Upshaw, a Hall of Fame player, was ridiculed by misguided members of the media because he worked with Tagliabue and Pete Rozelle on growing the league rather than focusing solely on the players? percentage of revenue. A smaller percentage of a bigger pie can be significantly more profitable than a bigger percentage of a smaller pie.

My point in bringing all this up is there is a terrific opportunity for the NBPA?s next executive director. He will be provided the chance to influence the direction of basketball in a way Hunter was not.

In fact, the new executive director should seek the position with the clear goal of being a transformative figure in the world of sports. As I have argued in previous columns, the NBA should set its sights on catching the NFL in terms of relevancy and popularity.

Basketball is the sports world?s No. 1 underachiever. Everyone ? male and female, short and tall, fat and skinny ? plays and understands the game. The temptation to use performance-enhancing drugs isn?t as pervasive (baseball) and it's not as rife with injury risks (football). And the game is blessed with sports? most charismatic and interesting stars.

What basketball ? not just the NBA ? has lacked is leadership and synergy. The new executive director will be assuming power at the perfect time. All signs point to the NCAA instituting radical change. The commissioners of the power conferences are demanding change. The public is demanding change. Sports Illustrated?s Pete Thamel wrote a story last week suggesting ?seismic? change within the NCAA.

Football and men?s basketball are driving this movement. The NBA and NFL players? unions should play large roles in how young football and basketball players are governed and developed before they reach the professional ranks.

Billy Hunter?s lack of vision always frustrated me. He never recognized the power of his position or he never had the energy to galvanize the necessary support to wield the power that was within his reach.

It?s my hope that the next NBPA executive director seizes that power and uses it to improve basketball and the entire system that shepherds a 13-year-old prospect into the professional ranks. If he does that, the new executive director could be an important figure beyond the world of sports.

In the aftermath of the George Zimmerman verdict, there is a debate raging around racial profiling, black criminality and who bears responsibility for addressing these issues. The topic is being exploited by the talk-show crowd on both sides of the political aisle.

Throughout this country?s history, sports have played a crucial role in bringing us all together, helping us understand each other and find common ground. Keep in mind, Jackie Robinson and Branch Rickey were nearly two decades ahead of the civil-rights movement. Robinson?s success with the Brooklyn Dodgers inspired the civil-rights movement.

The NBPA, with its black leadership and primarily black membership, can inspire a new movement. As black people, we don?t do enough to control our own destiny. For a multitude of reasons, including mass incarceration, we don?t do a good enough job taking responsibility for molding and leading our young people along the right path.

Football and basketball, sports reliant on the talent of young black men, are driving the collegiate power structure ? the commissioners of the five power conferences ? to reshape the way the NCAA conducts business. Decisions are being made about young football and basketball players and there will be no significant black voices influencing those decisions.

I don?t blame white people for that. I blame us. I blame Billy Hunter and DeMaurice Smith. I blame LeBron James, Kobe Bryant, Ray Lewis, Charles Woodson, Kevin Durant, Adrian Peterson, Ndamukong Suh and all the other professional black athletes who don?t think it?s their responsibility to play an active role in how their games are governed.

By dangling the possibility of returning 19-, 20- and 21-year-olds to college basketball, the NBPA could dictate the terms of NCAA reform, and those reforms could very well include compensation for those athletes and year-round academies for teenage prospects.

After winning his second NBA title, LeBron James answered his critics by explaining that the deck was stacked against him at birth and statistics showed that someone from his background should be dead, in jail or trapped in poverty.

In my opinion, it?s LeBron?s responsibility to do what he can to make it easier for other kids ? particularly athletes ? born into a similar situation to find the path to a better life. One of the best things he could do is force the NBA and the NCAA to involve themselves with the development of promising athletes at age 12 or 13.

Kids are pledging allegiance to gangs at that age. Why not bait them into pledging allegiance to an academic-based athletic culture/academy at that age? Only a handful of them may make it to the NBA, but they will all benefit from the experience and the overall game of basketball will benefit, too.

The new executive director of the NBPA will be staring at a historic opportunity. I hope he?s not just another puppet looking to collect a fat paycheck.

Source: http://msn.foxsports.com/nba/story/jason-whitlock-basketball-has-vast-potential-but-who-will-tap-it-stu-jackson-billy-hunter-steve-mills-isiah-thomas-072813

Michelle Knight Harris Teeter NCAA Football 14 Steam Summer Sale 2013 Randy Travis in critical condition stacy keibler stacy keibler

U.S., Japan Seek to Calm Asia Territorial Tensions

? Invalid email address.

? You can't enter more than 20 emails.

? Seperate multiple addresses with Commas.

? Must enter an email address.

? You must enter the verification code below to send.

? Invalid entry: Please type the verification code again.

Source: http://online.wsj.com/article/SB10001424127887323610704578629862418432322.html?mod=rss_about_china

Christmas Story after christmas sales case mccoy case mccoy UFC 155 Jack Klugman merry Christmas

Pope discusses women in the church, divorce, his own spirituality ? Catholic News Service


CBC.ca
Pope discusses women in the church, divorce, his own spirituality
Catholic News Service
ABOARD THE PAPAL FLIGHT FROM BRAZIL (CNS) ? From his personal prayer life and spirituality to the role of women in the church and the pastoral care of the divorced, Pope Francis responded to several questions about church teaching and ministry July??
Pope Francis On Gay Priests In Catholic Church: 'Who Am I To Judge?'Huffington Post

all 116 news articles??

View full post on spirituality ? Google News

Source: http://spiritualminute.org/pope-discusses-women-in-the-church-divorce-his-own-spirituality-catholic-news-service.htm

splunk dark shadows iau msft etan patz obama dog doug hutchison

Monday, July 29, 2013

Will Google finally have a TV hit on its hands with Chromecast?

Photo of Chromecast device by Gary Reyes/San Jose Mercury News (Gary Reyes)

Is this it? Will Chromecast finally give Google its must-see TV (gadget)? Here's a look at why or why not ? after the flops that were Google TV and the Nexus Q ? the third time might be the charm for Google and Internet TV.

Chromecast is a 2-inch dongle (raise your hand if you love that word, too) that allows users to view Internet-based videos such as those from YouTube or Netflix on their big-screen televisions. When Google unveiled the device this week, it threw in a sweet deal: a free three-month subscription to Netflix. But alas, Google told the Los Angeles Times that the promotion has been canceled because of ?overwhelming demand.' Score one for the why column?

As the Merc's Brandon Bailey and Troy Wolverton wrote, Chromecast has limited capabilities. But some analysts are bullish on it, especially because it costs only $35. And unlike Apple TV's Airplay, Chromecast is platform-agnostic. ?I think it's a brilliant end run around the complexity of other Internet TV solutions,' said Forrester analyst Sarah Rotman Epps.

But Brandon and Troy also talked to analysts who were skeptical, and their reasons are similar to those raised by others. There is already a plethora of devices that allow people to watch Internet content on their televisions, including game consoles, Roku, Airplay, and smart TVs themselves.

In addition, Chromecast is still a baby, so it hasn't had time to play with others yet: Only Netflix has an app for it, but Pandora and others are working on theirs. Roku, another small device that plugs into televisions and streams online content, boasts more than 750 channels, including Hulu and Amazon.

Some have done point-by-point comparisons of Chromecast against Roku and Airplay: Roku wins in content, Chromecast wins in cost and Airplay wins on connectivity, according to the Huffington Post.

Marketing Land's Danny Sullivan likes that users of Chromecast can search for content using the god-given keyboards on laptops or mobile devices, a step up from clunky searches using ?dumb' remotes. And here's another possible advantage Roku has over Chromecast. Roku doesn't sell content, so it's in the best interests of those that do to make apps for it. On the other hand, competitors such as Amazon or Hulu might not want to make things so easy for Google's handy-dandy little dongle.

Source: http://www.denverpost.com/technology/ci_23752587/will-google-finally-have-tv-hit-its-hands?source=rss

2 Chainz Big Brother 15 BET AWARDS 2013 Yarnell Az Arizona fire cirque du soleil Confederations Cup

Sony Pictures Studios hosted the snazziest Media Day in the country on Friday. G...

Sorry, Readability was unable to parse this page for content.

Source: http://www.facebook.com/photo.php?fbid=10151553471411801&set=a.429660611800.183664.62986931800&type=1

baltimore ravens ravens Ravens vs Patriots 49ers Vs Falcons Mama Movie flyers epo

Obama calls Korean War a victory, honors veterans

By Matt Haldane

WASHINGTON (Reuters) - Commemorating the 60th anniversary of the armistice that ended the Korean War, President Barack Obama said on Saturday that U.S. troops and their allies achieved victory in that conflict despite a lukewarm reception when they returned home.

The war ended in a stalemate in 1953, with the absence of a peace treaty resulting in a demilitarized zone that now separates North and South Korea. Pyongyang commemorated the day with a massive military parade and declared victory as well.

"Here, today, we can say with confidence that this war was no tie. Korea was a victory," Obama said to cheers from an outdoor crowd populated by war veterans from the United States and South Korea.

"When 50 million South Koreans live in freedom ... in stark contrast to the repression and poverty of the North, that's a victory; that's your legacy," he said.

The Korean War started in 1950 when the United States rallied the United Nations to send troops to counter the North's invasion of the South.

Secretary of Defense Chuck Hagel, Vice Chairman of the Joint Chiefs of Staff Admiral James Winnefeld and representatives from the South Korean government attended the event, which included a wreath-laying ceremony conducted to "Taps" before the 19 steel statues of Korean War soldiers at the memorial on Washington's National Mall.

The chairman of South Korea's National Policy Committee, Kim Jung-hoon, who represented the country's president, Park Geun-hye, acknowledged the ambiguous end to a long-fought war.

"This armistice was not the result of mere negotiations at the table," Kim said. "It was signed after endless battles, countless sacrifices and pain endured by our veterans and their grieved families."

When U.S. troops returned home, Obama said they went right back to work, with their sacrifices seemingly unacknowledged in what would become known as "The Forgotten War."

"Unlike the Second World War, Korea did not galvanize our country. These veterans did not return to parades. Unlike Vietnam, Korea did not tear at our country. These veterans did not return to protests," Obama said.

"Here in America, no war should ever be forgotten, and no veteran should ever be overlooked."

About 5,000 people attended the event, according to the commemoration committee. The crowd was filled with South Koreans and Americans alike, with spectators singing the South Korean national anthem nearly as loudly as the U.S. anthem.

Obama also acknowledged the strong military ties Washington has with South Korea, where more than 28,000 U.S. troops are now stationed. For some younger Koreans, the continued presence of troops is controversial, but the crowd erupted in applause when Obama mentioned his commitment to U.S. military supremacy.

"Our allies and adversaries must know the United States of America will maintain the strongest military the world has ever known, bar none, always," Obama said. "That is what we do."

(Editing by Peter Cooney)

Source: http://news.yahoo.com/obama-calls-korean-war-victory-honors-veterans-222239520.html

what is autism the giver march 30 rimm pauly d project adrienne rich autism

Hugh Jackman Talks Working in Japan, Mutant Flaws, and The Wolverine

Sorry, Readability was unable to parse this page for content.

Source: http://www.reelz.com/movie-news/16606/hugh-jackman-talks-working-in-japan-mutant-flaws-and-the-wolverine

Las Vegas shooting Jerry Buss Chris Bosh wife josh duhamel presidents day mindy mccready mindy mccready

Have These Men Found The Key To Fighting Cancer?

Carl June and his group of researchers at U Penn may have found a cure for cancer.

What?s your full name?
Where are you?
What month is it?
What day of the week is it?

Walter Keller tried to speak, but no words came out, only a dry rasp. The man asking the questions had dark, close-cropped gray hair and a kind, level gaze.

Eventually the man left the room. Walt wriggled up in his bed. Someone put a hand on his shoulder and pressed him gently back into the mattress.

Walt?tall and rawboned, with marbly green eyes and muscles hardened by a lifetime of physical labor?tried to elevate himself. An earsplitting noise went off. A nurse came running in and told him to get back down. When she left, Walt found that the nurses had clipped an alarm to his bed that would alert them whenever he tried to get up. He ripped it off and threw it to the ground.

The man was back:

What?s your full name?
Where are you?
What month is it?
What day of the week is it?

Walt had to get out of this room. He had a baseball game to coach, over at the ball field in Upland, California. The Upland Pony Giants were waiting for him. Michael was waiting, the skinny kid with the cannon arm, and Cody, the kid who could steal two bases on one pitch. The game was starting in five minutes?didn?t anyone understand that?

Walt glanced to his side and saw his 19-year-old son, Dustin. Dustin was here, thank God. Dustin would listen.

?Dustin, get my shoes,? Walt croaked. ?Dustin, I have to get out of here. I?ll give you a ride on the boat.?

Walt knew his boat was right outside the door of the room?the wakeboard boat he drove every year up and down Lake Mohave in Nevada, giving water-ski rides to his grandkids. His boat was right here at the hospital. If he could only make it out of the bed, to the door, he could climb into the boat and drive it back to his house.

Dustin shook his head: broad shoulders, soft voice, cherubic face, dark brown hair.

?Dustin,? Walt said, eyes soaked with confusion, ?you are infuriating me.?

?

Walt wasn?t in California, as he thought. He was 2,700 miles east, in Philadelphia, where he?d come to be a guinea pig in a test of a new kind of cancer treatment. Leukemia had invaded his bone marrow and spread like a stain through his lymph nodes; the traditional options, including chemo and radiation, had failed. He was 58, and his body groaned with tumors potentially weighing as much as seven pounds. Walt needed something radically different if he was going to live. And the treatment he?d been given a few days ago was certainly that.

Over the past several years, a couple of hundred mice had received it, but Walt was only the seventh adult human. (Six men had preceded him, as well as a six-year-old girl.) The treatment wasn?t a chemo drug, and it wasn?t a vaccine. Instead, doctors at the University of Pennsylvania had tried to make Walt?s own body the drug. In an approach known as gene therapy, they?d taken his own immune cells, modified them to give them new powers, and injected them back into his blood.

Gene therapy represents a break from the medical past. Like open-heart surgery, antibiotics and low-cost medical imaging, it?s a ?disruptive? technology capable of changing the way doctors do business. It could transform how we treat many types of cancers in people of all ages?if it can be made to work. But that?s the problem. Before this trial at Penn?a Phase 1 trial, the earliest possible human test of a new treatment?gene therapy had scarcely worked in cancer, anywhere in the world. A typical gene-therapy experiment in cancer was as exciting as a sip of warm tea. Nothing happened, good or bad. In other kinds of gene-therapy trials, there had been tragedies: At Penn in 1999, in a trial run by doctors unrelated to the team treating Walt, a teenager with an inherited liver disease had died after a gene-therapy infusion sparked a runaway reaction.

But Walt?s doctors had done things differently than past scientists. Their approach was original and new. And, incredibly, they?d already succeeded in making tumors vanish in a few of the patients who?d come before Walt. Using their custom technology, the Penn physicians had jolted two cancer-riddled men into sudden apparent remission?an outcome dramatic enough to earn mentions on TV news and a write-up in the New York Times. In September 2011, the paper described Penn?s work as ?a turning point in the long struggle to develop effective gene therapies against cancer.?

But now, eight months later, at the Hospital of the University of Pennsylvania, something dramatic was happening inside Walter Keller?s body?a riot of cells and signals. His blood pressure had crashed, so doctors had pumped him full of fluid to raise it, and the fluid had blown up his neck like a balloon. Socks were wrapped around his bloated legs to help with blood circulation. His kidneys were failing. He shook at times with ?the rigors,? excruciating full-body shivers that made his whole body feel the way his heart would if he had just run up a huge hill.

Scientists don?t talk about ?curing? cancer. A cure is the hope so great, so seemingly out of reach, that it must never be invoked. They?ve built a wall around the word. Still, the Penn researchers?as careful as they were, as professionally sober and skeptical?couldn?t help but wonder: Was their small experiment the start of something that could one day affect thousands, tens of thousands, more? Was it revealing a secret about the human body that could point the way to treatments for other cancers, not just leukemia? There was no way to know until they gathered more data. They needed to show that the therapy was safe. And they needed to prove that the early patients?the men whose tumors they?d blasted away?weren?t flukes.

Which is why so much now depended on Walter Keller. If Walt?s condition improved and his tumors diminished, the trial would move forward, and the potential of the Penn therapy?the result of a decades-long quest of scientific passion and discovery?would continue to grow. But if he suffered harm, Penn would have to pause the trial and maybe stop it altogether. Then everything would spiral down. Other scientists would argue that gene therapy was a dead end. Funding would dry up; research would wither. The Penn doctors might never get another chance to prove the merits of their idea, and we might all lose out. It had taken 20 years to get to this point, and it could all be over in the space of a few moments.

?

1996, Bethesda, Maryland

Captain Carl June had a way of making science seem almost mischievous?something in the curl of his lip, the folding of his hands in his lap. He was an intense character even by the standards of the U.S. Navy medical community, which tended to attract driven personalities. He?d played football as a younger man. He was 42 now and ran ultra-marathons; his calves were like titanium rods.

He directed a research lab on a Navy medical campus. The main goal of his lab was to make the human immune system do things it hadn?t evolved to do. Improve it. ?Put it on steroids,? he liked to say.

June had a tinkerer?s temperament, a fascination with inventing tools to make new kinds of inventions possible. Some of this he had absorbed from his father, a chemical engineer in the San Francisco Bay area. As a kid, June planned to go into science, but then the Vietnam War came, he enlisted in 1971 and received a congressional appointment to Annapolis. He trained for a time as a sailor on a nuclear sub. ?Very cool technology,? June would later recall. ?And then the war was over, so they said, ?You don?t have to do this stuff. You can go to medical school.? So I did that, and it was cool.? After med school, the Navy sent June to Seattle to learn how to perform bone-marrow transplants. If there ever was a radiation leak on a sub, the Navy would need doctors to give the sailors new immune systems, which is essentially what a bone-marrow transplant does. The procedure saves lives, but at considerable risk; it?s estimated to kill one in five. June saw heroic transformations as well as tragic deaths.

Now, in his Bethesda lab, June mostly studied HIV, the virus that causes AIDS. It was another lens for looking at the immune system, its powers and limitations. HIV is so insidious because it infects the very immune cells, called ?T cells,? that would normally kill it. June wanted to know everything about T cells. But it was hard to study them, because it was hard to grow them in the lab. So June created a better way. Working with a quiet, meticulous researcher named Bruce Levine, June discovered that he could coat artificial beads with proteins that mimicked the natural cells that normally coax T cells to divide. The beads, round and about half the size of a cell, were made partly of iron; when you wanted to use the T cells that had grown, you just passed the cells and beads over a magnet. The beads got stuck on the magnet, and the cells flowed through.

June enjoyed his work at the Navy, and peers across the country respected his creativity??a real genius,? Laurence Cooper, an immunologist at the University of Texas MD Anderson Cancer Center, calls him?but by 1996, he?d begun to feel restless. The Navy only funded research into infectious diseases like HIV, and he wanted to study cancer. His wife, Cynthia, had recently been diagnosed with ovarian cancer. They had three kids in high school and college. June wanted to use what he?d learned about the immune system to tackle the disease. And more than that, he wanted to find a way to get his ideas out of the lab and into the wider world of suffering and need.

June retired from the Navy in 1996. For the next three years, he continued working in the same lab as a civilian, employed by a foundation, while caring for his wife as she endured chemo. ?I learned a lot about being on the other side of a bed,? June says, ?and what it?s like going through the ups and downs of cancer therapy. I had no idea of the impact.?

In 1999, Penn offered June a prestigious appointment at its medical school. It was the chance he?d been waiting for. He moved to Philly, bringing Levine with him, and launched a new lab to translate basic science into drugs that could be commercialized, including cancer drugs. Meanwhile, Levine began to build a pilot facility that could produce drugs and vaccines in small batches: the Clinical Cell and Vaccine Production Facility. It was like a biotech company in miniature. In 2005, Levine scaled it up, moving into a warren of renovated lab space in a hospital building off Spruce Street.

Some of its first creations were custom cancer vaccines for the benefit of June?s wife. ?She wanted to go for the home run,? June recalls. She wanted to see her kids grow up. He was sympathetic, of course; in her place, he?d have wanted the same. But in talking to some of his colleagues about risk, June came to realize that not everyone would. ?Some people are not risk-takers at all,? he says. For the first time in his career, June was forced to think about what it really meant, on a human level, to become a guinea pig in a cutting-edge medical trial?or to turn down that chance. What?s more rational? To fight, or to accept your fate with grace?

The vaccines didn?t work well enough to save Cynthia June. After five years of treatment, including two bone-marrow transplants, she died in 2001.

?

1996, Upland, California

Robin was on the phone. She was down at nearby Ralphs supermarket, where she worked checkout. The union had brought one of those mobile health vans to the store. Walt should come get a physical exam, she said. Why not? It was free.

To humor his wife, Walt drove to Ralphs and climbed into the van. He gave a sample of his blood. A few days later, he picked up the phone. ?There?s something wrong with your blood,? a voice said. ?We?re praying for you.?

Leukemia. Walt, it turned out, had the most common type: chronic lymphocytic leukemia, or CLL. Walt had always worried he might get cancer one day?his father had died of non-Hodgkin?s lymphoma, and Walt had spent decades sucking down wood-stain fumes in his job as a cabinet refinisher?but still, the diagnosis felt like an ambush. At 43, he was scared of losing everything he?d built. He?d come so far from the little house in neighboring Montclair, where he?d grown up poor and afraid.

One day when Walt was 14, his stepfather burst through the door, carrying a gun. He told Walt not to move. He grabbed Walt?s mother around the waist and pushed her out into the side yard. Walt heard a gunshot, then two more. He went into the yard. His stepfather and mother were both splayed out on the ground. The man had shot her, then shot himself. Walt stood there in shock. His mother was bleeding from her nose and ears. He went back into the house, got a pillow from his room, and put it under her head.

After the murder-suicide, Walt?s birth father moved back in. An alcoholic painting contractor, he was too drunk to work. He made Walt ride his bicycle to the liquor store to fetch whiskey. The eldest boy of six siblings, Walt had to drop out of school at age 16 to support his brothers and sisters.

So his current prosperity, 30 years later, struck him as faintly miraculous. Two grown daughters, Chelle and Shawna. A three-year-old son, Dustin, whose birth had leveled him with a joy so intense, he didn?t know what he?d done to deserve it. A spacious house with a courtyard and palm trees in Upland, just 15 minutes from Montclair but a world away, where Walt ran his own cabinet business and coached youth baseball. Walt wanted to see Dustin grow up; he wanted to see Chelle and Shawna start families of their own. He told his oncologist, Linda Bosserman, that he?d try anything.

After monitoring his cancer for two years, Bosserman started Walt on chemo in 1998. Up to three times a week, three weeks a month, Walt sat in a recliner as poison poured into him. One day he came home from a chemo treatment and Dustin was there, looking up at him. Dustin?s dark brown hair was only thickening as Walt?s was falling out. ?Dad,? he said, ?if you die, how am I going to talk to you??

The chemo was preparation for a course of full-body radiation, which crisped Walt?s skin and left his mouth so full of blisters that he needed morphine to dull the pain. After that came a stem-cell transplant, a procedure in which blood is drawn from the body and spun in a centrifuge to extract pure stem cells, which can generate new, healthy bone marrow cells. Then, after chemo and radiation wipe out the bulk of the cancer, the stem cells are injected back into the veins.

The stem-cell transplant, in 1999, bought Walt five and a half years of remission. He built a rudimentary batting cage in his backyard and worked with Dustin there, sitting on an overturned milk crate in the cage and tossing his son dozens of underhanded pitches. When the cancer returned, in 2005, Walt went through the whole procedure again: more chemo, more radiation, a second stem-cell transplant. ?That?s like going to hell twice,? he says.

It worked, until it didn?t.

In 2010, when Walt was just shy of 57, he began to feel abnormally tired and weak. He knew what it meant. Eventually he went in for some blood work. The next time he saw Dr. Bosserman, in August, she spoke to Walt in a tone he?d never heard before.

His cancer was back again. And there were no good options left. A third stem-cell transplant wasn?t in the cards. None of his family members were a genetic match for a bone-marrow transplant. All Walt could do was place himself on a waiting list to receive a transplant from a stranger. In the meantime, Bosserman would start him on a third course of chemo and hope for the best.

Almost immediately after starting on the drugs, Walt sensed that he had reached the end.

Meanwhile, his sandy-haired daughter Chelle, a birthing consultant at a local hospital, started talking to him about heaven. She had a family of her own now, and was raising her children to know Jesus. ?Heaven is real,? she?d say, ?and we know how to get there. We?ll see each other again.?

Walt had never been much for church. But he thought about his love for his daughter, that feeling so powerful you can?t put it into words, and he thought about how God knows when you?re low and what?s in your heart, and suddenly it all made sense: He is using my love for my daughter to reach me. He is using Chelle as a vehicle.

He tried not to be afraid. He climbed into his van every day and went to work. In the van, he listened to Vin Scully call the Dodgers games on the radio, marveling at how Vinny could make you see the action in your head: every pitch, every hit and stolen base, a game of seemingly infinite complexity mastered and mapped.

One day, Walt was finishing up some French doors by the pool of a client when the man of the house rushed out, eyes aflame. ?Walt, Walt,? the man said, ?there?s a lady on TV, and they say they have a cure for what you have.?

?Ah, there?s no cure for what I have,? Walt mumbled, and went back to work.

When he got home that night, he turned on the evening news. The newscaster started talking about leukemia.

Walt?s cell phone lit up.

?

2004, Philadelphia

T cells. Carl June had an idea for a new kind of cancer treatment involving T cells, those building blocks of the immune system.

In their natural state, T cells usually aren?t able to kill tumor cells, partly because they can?t latch on strongly enough. But June was fascinated by scientific papers showing it was possible to change this. A few researchers?first an Israeli named Zelig Eshhar in the ?80s, then other investigators around the world?had discovered that you could force a T cell to stick to a tumor cell and kill it. To pull this off, you built an ?engineered T cell??a T cell never before seen in nature. You altered the T cell?s genetic blueprint by injecting a new gene into the cell. The new gene would tell it to build a new molecular limb. The limb, called a ?chimeric antigen receptor,? would sit partly inside the cell and partly outside, and it could send signals either in or out. One signal it could send was: kill. Another was: replicate.

June loved this approach. So elegant. Put the immune system on steroids. What if you could train the body to fight cancer on its own? What if, instead of replacing a patient?s immune system (as in a bone-marrow transplant) or pumping him full of poison (chemo), you could just borrow some cells, tweak them, and infuse them back into the patient? In theory, the engineered cells would stay alive in the blood, replenishing themselves, killing any tumors that recurred. It occurred to June that one infusion could last a lifetime.

He was also excited by the flexibility of engineered T cells. Normally, a drug for one kind of cancer couldn?t ever work on another kind; you had to start over from scratch. But here, since you were starting with a T cell and adding a limb, you only had to change the shape of the limb. You could snap a new piece on the end, like a LEGO, that fit into a molecule on the surface of a breast-cancer cell, or a pancreatic-cancer cell, or whatever kind of cancer you wanted to attack.

June and Levine had actually tested engineered T cells before, in patients with HIV. The cells hadn?t cured anyone, though they did improve immune-system function. But June wondered if the cells could work in cancer. Around 2003, he started discussing a cancer trial with a few colleagues at Penn, including Levine and an oncologist, David Porter. Porter ran the bone-marrow transplant program at Penn, and he was passionate about investigating new treatments. Together, the men decided to work toward a test of engineered T cells in patients suffering from a certain family of leukemias, including chronic lymphocytic leukemia.

In 2004, June and Porter won a $1 million grant from a small foundation, the Alliance for Cancer Gene Therapy, created by two parents whose daughter-in-law had died of breast cancer. It was enough to get started. But before they could make much progress, scientific opinion shifted against them. By 2006 and 2007, teams at other universities had run their own trials of engineered T cells in cancer patients. Invariably, the cells didn?t replicate well and simply died in the blood. In one trial, they only lasted a day. The cells had no effect. They didn?t work. The whole idea was starting to seem like a bust.

This is a story about science. But science is performed by people, and people are fallible, and people are stubborn. Carl June had seen before how a field could get it wrong. Back in med school, he used to lift weights pretty seriously. Some of the guys in his gym started experimenting with anabolic steroids. June saw them suddenly zoom from benching 220 pounds to a superhuman 320. The stuff obviously worked. But when June looked up steroids in his med-school textbook, it said that they were bogus; they only appeared to work because they made your muscles retain water. It wasn?t until decades later, when juiced-up sluggers like Barry Bonds ruled the ballparks, that sc ience acknowledged steroids really could build muscle.

Even as others sprinted away from engineered T cells, June ran toward them. He couldn?t shake a sense that they were so beautiful, they had to work. The concept was sound; only the execution was lacking. It was a matter of getting the details right.

June thought he and his team at Penn could succeed where others had failed. They had a few advantages. One was a better way of growing T cells?the June/Levine system of magnetic beads, developed at the Navy. Another advantage was a custom ?vector,? a sort of molecular truck for hauling new genes into a T cell. Other teams had built their trucks out of parts from viruses that cause leukemia in mice. Penn?s truck was more efficient, because its researchers had made the bold decision to build it out of HIV. HIV works by squirting its genes into T cells. Nothing on Earth is better at this task. Why not exploit it? In the lab, a researcher named Michael Milone, along with others on June?s team, had snipped away at the virus, removing the dangerous parts?the ones that let it multiply and cause AIDS?while keeping the basic chassis.

Penn had a set of unique tools, then. And the doctors used those tools to create and test various shapes of molecular limbs that no one else had tried. They injected their custom T cells into mice that had been genetically modified to accept human cells. By 2007, after testing several varieties of cells, Milone had identified one that seemed to work best, and was able to show that it could cure leukemia in mice.

Of course, scientists can cure a lot of diseases in mice that they can?t cure in people. It?s far easier and cheaper to do mouse trials than human trials. The first human-sized batch of vector?40 liters, filtered down to less than a shot glass?s worth of slightly opaque fluid for use in the trial?would cost $300,000 to make. The problem now was getting the money to scale up from mice to humans, which meant finding a funder who believed in the idea.

No one just hands money to scientists. They have to fight for it. It turned out that the main funder of cancer research in the U.S., the National Institutes of Health, didn?t want to pick up the check. Influential scientists there didn?t think engineered T cells could ever work. June reached out to a few drug companies, but they were no help, either. Big Pharma didn?t see a way to make money; the therapy was too different, too logistically demanding.

In 2008, the economy crashed, and June struggled to find money to pay his postdocs and lab assistants. He considered canceling the trial. Eventually, though, he managed to patch together funds to make the first batch of vector. It was enough for three patients.

?

2010, Philadelphia

They could feel the cancer through his skin?acorn-sized nodules of tumor in the lymph nodes under his arms. He was Bill Ludwig, a 65-year-old retired corrections officer from New Jersey. He?d come to Philly to be Patient No. 1.

At HUP, nurses hooked him up to an ?apheresis? machine, which spun his blood in a centrifuge, separating his red cells and platelets from his T cells. The T cells then traveled to Levine?s Clinical Cell and Vaccine Production Facility, which was full of biosafety cabinets and scales and flasks, and refrigerators named after characters from The Simpsons: the Otto Fridge and the Maggie Fridge, along with the Krusty Freezer. Levine and his technicians added the magnetic beads and the vector to Ludwig?s T cells and put the cells in a nutrient medium that provided everything they needed to divide and grow. At this point, the mixture was the color of Earl Grey tea. The cells sat in a bag for the first few days, then were placed on a machine that rocked them gently to promote further growth. Then a magnet removed the beads, and the cells were frozen to preserve them while Levine and his team performed quality-control tests required by the FDA. After the tests were complete, the frozen bag of cells?about three ounces? worth, or a quarter-can of soda?was taken down to Bill Ludwig?s bedside (a journey that involved rides on two elevators) and warmed in a water bath. Then a nurse hung the bag on a pole and connected it to an IV line. The fluid flowed into Ludwig.

Five days later, his temperature spiked.

David Porter studied a chest scan to try to figure out what was going on. He saw that Ludwig?s lungs looked like they had pneumonia, which is common in CLL patients. The doctors treated it with antibiotics, and it went away. But Ludwig?s fever only increased. Over the next few weeks, he grew sicker and sicker, quaking with chills, sweating with fevers. The doctors worried that maybe he was suffering from something called cytokine release syndrome, an immune system overreaction that had killed patients in other trials. Soon Porter and the other Penn doctors were dealing with end-of-life issues, like whether to put Ludwig on a respirator. Ludwig?s wife called the whole family to the hospital, fearing he would die.

In all the commotion, no one thought to look at the patient?s tumors. It wasn?t until Day 21 that an intern tried to palpate the lumps under Ludwig?s arms?and couldn?t find them.

Ludwig began to feel better. His blood counts improved; his fevers subsided. On Day 30, the team performed a battery of tests, including a CAT scan. When P orter looked at the scan, he couldn?t see any evidence of cancer. Then the team extracted some bone marrow and analyzed the cells several different ways. The first two tests showed no tumor. The third and most sensitive test showed less than one tumor cell in several hundred thousand, which more than met the definition of a complete clinical response.

Carl June thought it had to be a mistake. He asked for another bone-marrow biopsy, and for the tests to be repeated. The results of the second tests were the same: no cancer. If Ludwig still had the disease?and he might?it was beyond the current ability of medical science to detect.

The doctors obviously took this as good news, but it wasn?t as dramatic a moment for them as you might think. Medical investigators working on new kinds of treatments tend not to expect wild success. ?We?ve all been involved in new approaches in treatments where the first patient, it?s miraculous, and then you treat nine people and it doesn?t work again,? Porter says. Besides, it didn?t make sense to celebrate when they didn?t yet know what was going on. All the team had was a suspicion?a rough hypothesis about what was happening inside Bill Ludwig?s body.

Sometimes when doctors give chemo drugs to patients who have never had chemo before, large quantities of tumor cells die and crack open all at once, releasing high levels of toxic junk into the blood: chemicals that mess with heart rhythms and cause other dangerous problems, as well as uric acid, which clogs the kidneys. This is called tumor lysis syndrome. Porter and June hoped that tumor lysis was the cause of Ludwig?s fevers, because if it was, it meant that the T cells were working; they were killing Ludwig?s tumors. But if it was indeed tumor lysis, it was a kind never seen before. Usually, symptoms of tumor lysis occur within a day or two of treatment. Ludwig hadn?t gotten sick until Day 5.

The Penn doctors went on to treat their second patient, who responded much as Ludwig had, with severe flu-like symptoms that swelled and ebbed; follow-up tests revealed that much, but not all, of the patient?s cancer had been eliminated. Two successes were better than one, but two could still be a fluke; two could be an accident. It wasn?t until the doctors treated Patient No. 3, a 64-year-old Bucks County man named Douglas Olson, that they got a clear picture of what they were achieving.

Olson, a scientist himself and a longtime patient of Porter?s, had come into the trial with three pounds of tumors in his body. The tumors had proven resistant to all other therapies, and he didn?t want to try a bone-marrow transplant. ?If you survive it,? Olson says, ?you may not be cured, and you can?t do it again. So this trial was a chance to beat this thing.?

Something was different about Olson, something that made him a particularly useful test case: His T cells hadn?t grown well in the lab. The team could only give him one one-hundredth of the dose of T cells given to the first patient. It was such a low dose that some colleagues at Penn didn?t think it was ethical to treat the patient at all. Says Porter, ?There were people who were going to insist he sign a consent that he knows this is futile. And we just argued, ?We don?t know that.??

The team won the argument and went ahead with the infusion. Fourteen days later, Olson woke up with fevers and chills. He called Porter, who told him to come in for some tests. ?Now I had a sense of what was going on,? Porter says. ?That this was, in fact, good news.?

Over the next week, Olson felt nauseated and suffered from diarrhea; he couldn?t eat. (As the doctors would later discover, what was making the patients feel like they had the worst flu of their lives was cytokine release syndrome.) On the evening of Day 21, Porter was walking across the Penn campus when he got a text message on his pager. It was a series of lab results on Olson.

June got the results the next morning in his office. He scanned through columns of numbers, mouth agape. One of his colleagues, Michael Kalos, had spent years designing a series of ultra-precise assays to measure the activity of T cells in the blood, and now Kalos?s assays were telling an incredible story. On Day Five, there had been almost no engineered T cells in the patient?s body. By Day 18, there were billions. They had multiplied a thousand-fold from the original tiny dose. Almost every T cell in the patient?s body was one of Penn?s special genetic creatures. The patient was growing the drug in his body.

What?s more, the lab results painted a picture of cataclysm in Olson?s blood. As the T cells grew exponentially, the patient?s kidneys had begun to shut down, and all sorts of chemicals associated with tumor lysis syndrome were wreaking havoc. It was really happening, all of it?cell growth, tumor death?exactly as the team had intended.

Two days later, Olson?s bone-marrow biopsy came back clean. Three days after that, doctors discharged him from the hospital, an apparently healthy man. ?I was absolutely cancer-free,? Olson says. ?I gotta tell you, every time I say that, it just gives me the shivers.? The day he left the hospital, Olson drove to Maryland with his wife, to the Annapolis Boat Show, and bought an 18-foot sailboat.

The temptation was to say that pounds of tumors had ?melted away,? but melting implied a gentle process, and what had happened to the tumors was more violent than that. They?d been either torn to shreds directly by T cells that acted like serial killers, moving from one tumor cell to the next, slashing membranes and spilling innards, or they?d been destroyed by enzymes secreted by the T cells.

In follow-up tests six months later, the team would find high levels of engineered T cells still alive in Olson?s blood. And no detectable tumors.

?

It was ingrained in them, through their training, to resist celebration. After June and his colleagues got the initial results for Olson, they thought about all the things they still didn?t know. Why, exactly, had the therapy worked so well? Was it the particular structure of the engineered cells? Was it the way they?d grown the cells, using the body as a sort of bioreactor? Was cancer still lurking below the threshold of detection?

They knew it would take years to answer these questions. They also knew that ?something unprecedented had happened,? June says. The responsible thing to do with such data is to publish it and let other scientists take a look, and that?s exactly what the Penn doctors did. They submitted papers to two prestigious journals, the New England Journal of Medicine and Science Translational Medicine, and as the papers circulated, scientists quickly recognized their significance?especially the handful of researchers who, like June, had always believed that this approach could work. ?The Penn trial was definitely a turning point,? says Michel Sadelain, a researcher at Memorial Sloan-Kettering Cancer Center who has made important contributions to the study of engineered T cells. ?In the first three patients Carl treated, two of them showed a very dramatic response. It couldn?t be any more dramatic. They had large tumor burdens that essentially vanished.? Laurence Cooper at MD Anderson describes the transformation of the initial patients as ?a sort of Lazarus moment.?

Lazarus moment or no, there were still scientists who didn?t buy that Penn was onto something big. The argument for skepticism rested less on science than logistics. Penn was a small operation?a boutique. Sure, they could treat three patients, but what about 300, or 3,000? Penn hadn?t shown it could even begin to meet the need. Maybe the therapy was inherently impractical.

No one was more painfully aware of Penn?s limitations than David Porter. In late 2011 and early 2012, after news of the breakthrough spread from the scientific literature into media around the world, more than 5,000 emails flooded into Penn, begging for access to the trial. ?She is our first-born and only girl,? went a typical letter from a mother and father hoping to get treatment for their daughter with leukemia. ?We both love her very very much.?

Porter read these letters with anguish. He knew Penn only had the capacity to treat seven or eight more people over the next year. Besides, the therapy was still so new. He didn?t know all the side effects yet. It wouldn?t be responsible to throw the trial open to more than a few.

How do you explain the need for scientific caution to the parent of a dying child?

Here is what Porter ended up telling people: ?We?re doing this as fast as we can.?

?

Walt got into the trial because his family fought for him. It?s really that simple.

Penn had set up an online application for the trial. Walt wasn?t good with computers, so his eldest sister, Nancy Nelson, a woman in her early 60s with dirty-blond hair and glasses, filled out the form and hit SEND.

Nancy and Walt had always been extremely close; they?d bonded as kids in Montclair, relying on each other to process the trauma of their mother?s murder. Nancy had already decided that if Walt got into the trial, she would leave California to be at his side for however long it took. Walt?s wife, Robin, couldn?t do it. Their relationship had lately become rocky; besides, she had to stay at her job to keep Walt?s health insurance current.

Nancy received a brief email response from Penn?a form letter. Then, nothing. ?We figured out pretty quickly that it was just going into a black hole,? she recalls.

Eventually, after two weeks of calls and prayers, Walt?s daughter Chelle connected with a researcher who worked for David Porter. They spoke for half an hour. ?He explained to me that it was very high-risk,? Chelle remembers. ?That my father could die. The new cells could eat up his whole body.? She asked the researcher a question: If it were his father, what would he do? According to Chelle, the man said, ?Oooooh. I don?t know.?

Chelle didn?t hesitate: Her father had made his wishes clear. She set up an appointment for Walt to meet Porter.

Walt and Nancy flew to Philadelphia for the meeting in November 2011. ?If you let me into the trial,? Walt told Porter, ?I promise I?ll be the best patient you?ve ever had. I promise I?ll make it.? Porter took this as a good sign; an early-stage medical trial demands ?some incredible amount of optimism? on the part of the patient. It also boded well that Nancy was here, wearing a silver necklace that said CURE WALT. Porter didn?t commit, though. He told them how difficult the journey would be. A bone-marrow transplant was the tried-and-true option.

Walt said no. He wanted this.

Porter agreed to run blood tests to see if Walt?s cells would respond to the vector. In March 2012, Walt got the call: He was in.

The next few months were among the most agonizing of his life. His health began to fluctuate, because his leukemia was progressing. Doctors at Penn requested extra tests. Next, Penn ran out of vector?they?d used up their first two batches on the first six patients?and he had to wait for a new batch to be ready. He had to cool his heels. By now, he and Nancy had left California and come to the Philly area in anticipation of Walt?s infusion. They were staying in Cheltenham, in a free hotel for cancer patients and their caregivers called Hope Lodge, run by the drug company AstraZeneca. They ate their meals in a communal dining room, chatting with the other patients about the Phillies.

Then, in April 2012, Penn suddenly suspended the trial. They?d begun treating their first child patient, Emma Whitehead, a six-year-old girl who suffered from acute lymphoblastic leukemia, a disease similar to CLL. After Emma received her dose of T cells, her body?s immune system had revved up, releasing cytokines that caused fever, nausea, hypoxia (low oxygen) and low blood pressure. Doctors decided to administer an anti-cytokine agent called tocilizumab. They paused the trial to make sure she?d be okay.

When Emma recovered, the trial resumed. Walt finally received his infusion of T cells on Tuesday, May 15th. Chelle couldn?t be there, so she texted Nancy a prayer to read out loud:

Father God, we ask for your blessing on these cells. Let this blessing flow right from you to Walt. May these cells be of You, Lord. May they heal, restore and give life. ?

?

The first night, Walt spiked a fever.

This was unexpected. Previous patients had taken five to 14 days to get sick. The doctors tested Walt?s blood. What they found surprised them: By Day 3, Walt had higher than expected levels of engineered T cells in his blood. His bioreactor was churning with astonishing speed.

Walt started feeling better over the next few days. He even penned some coaching advice for his players in an online journal Nancy had been maintaining:

Wyatt, remember to pick up the target early and on your fastball make sure to keep your hand behind the ball.

Alec, don?t worry about your speed. Your strength is hitting your spots and changing speed of pitches.?

On the morning of the sixth day after infusion, Nancy woke up in Hope Lodge and checked on Walt. Walt wouldn?t get out of bed. He seemed more tired than ever. Nancy couldn?t get him to eat or to drink much water. She called Porter, who said to bring him to the hospital right away. When they arrived, a nurse tried to get blood from Walt but couldn?t find a vein. His blood pressure had crashed. Doctors rolled him into the emergency room.

From here on in, Walt?s memories are fuzzy. He has a particular way of characterizing this lost time: ?I fell into the ditch.?

His kids came to Philly when they heard he was worsening. Chelle arrived on the night of Wednesday, May 23rd; Shawna and Dustin came the next day on a red-eye flight, sprinting from the airport to a cab and from the cab to the hospital. ?I thought I was coming to say goodbye,? says Shawna, a 38-year-old with curly hair who works in an orthodontist office in California. When she finally got to Walt?s room, she had to step back and take a minute to compose herself. It was mostly his eyes: They looked like they were bleeding.

The kids slept fitfully in chairs next to their father?s bed. They chatted with the nurses caring for Walt and looked forward to the twice-daily visits from Dr. Porter, whose archetypically calm bedside manner helped reassure them that Walt would be okay. Porter had seen many of Walt?s symptoms crop up in previous patients, and by now he had a better sense of how to deal with them. He knew he could tamp down the activity of the T cells by administering tocilizumab, the anti-cytokine agent. What he didn?t know was this: By suppressing the T cells, would he also prevent them from killing Walt?s tumors?

When Porter asked Walt if he wanted the anti-cytokine agent, Walt shook his head vigorously: He didn?t want to risk stopping the beneficial part of the reaction.

Let these puppies work, Walt thought.

?

By Friday night, though, 10 days after infusion, Walt was no longer able to make decisions for himself. He started babbling to his sister and his children about Elvis Presley. He told them he had to get out of his bed.

Porter talked to Chelle and Nancy, and they all agreed that even though it might reduce the efficacy of the T cells, they shouldn?t wait any longer to administer the agent. The staff gave it to Walt, then moved him into the intensive-care unit.

The scariest moment for Walt?s family came a short time later, around 10 on Saturday night, when Walt started to repeat the same phrase over and over. ?I need to go,? he said, a faraway look in his eyes. ?I need to go. I see the white wedding.? To Dustin, it was like something out of a movie: His father was telling him that he could see the light, that he was sick of fighting and he wanted to die.

Chelle said, ?That?s okay, Dad. You can go.? She?d miss him if he died, of course, but the way Chelle saw it, God was in control, not the family. If God wanted to take Walt, that was His will.

?No!? Shawna screamed.

Dustin began to cry. ?No, Dad, don?t go.?

Dustin held his father?s hand. Walt gripped back, tightly. Then he let go.

This is it, Dustin thought.

But then Walt opened his eyes.

He did that a few more times, gripping and letting go, gripping and letting go. Finally, he slept.

The next morning, when Walt woke up, his family thought he looked better. It seemed like he had regained his voice and some of his vigor. The anti-cytokine agent was working. Over the next few days, Walt?s physical state continued to improve. His thinking was still muddled, though, which meant that things got harder for the family, not easier, because now Walt could actually pull himself up onto the rails of his bed in an attempt to escape. Nancy and the kids took turns playing prison guard. They would lie on top of him, hug him close, just to keep him down. There was a rope above Walt?s bed attached to a hook that the nurses could use to hoist him up. At one point, Walt grabbed onto the rope with both hands like it was a water-ski line and said to the nurses, ?Hit it,? which is the signal a water-skier gives to the speedboat driver to start the engines.

Then, over the next several days, Walt was moved to a regular hospital room and started to climb out of the ditch. Nancy had taken to playing Motown music on her iPad. One day she noticed Walt humming along to ?You?ve Really Got a Hold on Me?:

I don?t like you, but I love you. ?
Don?t wanna kiss you, but I need to.

Another time, Walt elevated himself on the side of the bed and started jiggling. A nurse asked him what he was doing. ?Shaking my booty,? Walt said, and sang: Shake shake shake, shake shake shake your booo-tay.

The day they really knew Walt was back, though, was the day Dr. Porter walked into the room to ask the four questions?

What?s your full name?
Where are you?
What month is it?
What day of the week is it?

?and Walt answered them before Porter could even speak: ?I?m Walter Robert Keller, I?m at the Hospital of the University of Pennsylvania, it?s May, and today?s Thursday.?

?That was awesome, Walt,? Porter said.

Soon Walt got out of bed, moseying through the hallways with a walker. Around that time, on June 5th, Porter took a sample of Walt?s bone marrow to check on the status of his cancer. The lab report came back six days later, on June 11th. Accompanied by several staffers, Porter came to Walt?s room to give him and Nancy the news.

The doctors clustered around Walt. ?All of us were trying not to jump up and down,? Porter recalls.

Before the trial, 90 percent of Walt?s bone marrow cells had been cancerous. Now, doctors couldn?t find any trace of the disease, Porter said. They still had to do more tests. But Walt appeared to be in complete remission. Up to seven pounds of tumor, obliterated, gone.

?His eyes were, like, lit up,? Walt recalls of Porter. ?When someone tells you you have cancer, and then when someone tells you you don?t have any?oh, it was like a monkey just jumped off my back.?

?

Walt stayed in the hospital for a few more days, working with a physical therapist to regain strength in his atrophied muscles. He and Nancy moved back to Hope Lodge for a time, then returned home to California in July.

Meanwhile, in Philly, the Penn team went on to treat adult patients No. 8, 9 and 10, as well as a second child, for a total of 12. (One of the patients in the second trio?4, 5 and 6?had a partial response to the therapy, while two others saw no effect on their cancer; another adult among the first 12 patients also did not respond.)

Last December, at a medical conference in Atlanta, the team presented its results to a rapt audience. The data boiled down to this: Nine out of the 12 patients, including both of the children, had responded to the therapy. Nine out of 12 had grown the engineered T cells in their bodies. Nine out of 12 had experienced some degree of tumor lysis syndrome and had seen their tumors vanish, either partially or completely.

Even more encouraging were the follow-up data on the two early cases of compete remission?patients No. 1, Bill Ludwig, and No. 3, Douglas Olson.

One big question all along has been the durability of the T cells. How long will they stay alive in the blood? Months? Years? Will cancer return in these patients? Doctors don?t know. ?I don?t think we?ve proven that we?ve cured anyone,? Porter says. Still, when Ludwig and Olson returned to Philly for their two-year checkups in the fall of 2012, they told doctors they felt great. The team checked their blood. The T cells were still alive, two years after infusion. Cancer undetectable.

?I think of these guys as the first astronauts, right?? says Levine. ?They didn?t know what they were getting into. They signed up for something, and it?s wonderful to see how it?s turned out.?

?I mean, I thought it might work,? June says, ?but I didn?t think it would work as well as it did.?

?

Science is incremental. It?s a slow and global grind, a steady accumulation of facts wrested from failure. But every once in a while, there really is a leap, and a small group of people can change how thousands think about the possibilities.

Carl June argued for years that engineered T cells could work, without much to show for it. But thanks to the trial, people are starting to listen. Even Big Pharma wants in.

For months, Penn has been working with the Swiss pharmaceutical giant Novartis, which manufactures the cancer drug Gleevec and the ADHD drug Ritalin, among others. According to the terms of a deal struck last year, Novartis will soon construct a new building on the Penn campus, the Center for Advanced Cellular Therapies, where Penn researchers will partner with scientists from Novartis to develop the T-cell technology.

Pharmaceutical companies have collaborated with universities before, but never to address the unique challenges that lie ahead for this particular drug. Novartis will help Penn learn more about the inner workings of the therapy so they can better channel and control it, hopefully sparing future patients ordeals like Walt?s. It will pay for the costly Phase 2 and Phase 3 trials required to win FDA approval. It will help test the technology in other kinds of cancers: June and his team now have trials in the planning stages for mesothelioma (a lung-lining cancer); pancreatic, brain, prostate, breast and ovarian cancers; and other blood cancers. And for the first time, a pharmaceutical company will design a manufacturing system that takes blood from the patient, modifies it in the lab, and gives it back to the patient. The biggest challenge here isn?t proving that the drug works; the biggest challenge is making it.

These days, Carl June spends a lot of time thinking about biology on an industrial scale?the unsexy details of cell cultures and workflows in the factory he wants to build. But when he?s not thinking about the very large, he marvels at the very small. At the power of the Penn trial, given its size. A few well-described cases ?can really change the whole field,? he says. A couple of brave men. Two kids. That?s all. And look.

?

2012, West Covina, California

?Nice and easy, okay?? Walt tells the starting pitcher of his Upland Underdogs, a 13-year-old named J.J. with orange sunglasses. It?s a bright October Sunday, and Walt is in the bullpen with J.J. before a game. ?You struck out nine guys on this team last time,? Walt says. ?Okay, remember, you?re like a tree falling in the forest, okay? Don?t overthrow.? A spindly arm wheels around, and the ball smacks into the catcher?s glove. ?Good, J.J.?

The opponents, West Covina, are batting first. Walt jogs out onto the field and takes up his position as first-base coach. He can jog now. He can stand in the sun and shout at the kids in the dugout to stop goofing around and pay attention to the pitcher?s moves.

It?s been three months since Walt came home from Philadelphia. His kidneys aren?t quite back to 100 percent. When he goes out in public, he sometimes wears one of his painting masks to protect his immune system, and from time to time his feet go numb and he has trouble pressing the gas pedal on his truck. Yet he can feel his body coming back. There are days when he wakes up clear-headed, when he?s full of weird energy and he wanders around confused until it suddenly occurs to him: This is what it feels like to be healthy. A year ago, Walt had given up planning for a future he didn?t think would ever come, but now he?s thinking about expanding his wood-fin ishing bu siness. He?s even started to wonder, half seriously, about scoring his ultimate dream job: pitching coach for a minor?and eventually major?league baseball team. Decades of coaching experience under his belt?why not?

Walt?s kids are here today, Dustin and Shawna and Chelle, watching in the stands, telling stories about the trial.

?It?s an indescribable feeling, finding out his bone marrow is clean,? Dustin says, gazing out at the diamond. ?It?s surreal. It?s still surreal. I?m in disbelief.?

West Covina cycles through three pitchers in four innings. The game finally tips in the fifth, when Walt?s team explodes for 15 runs. The rally-capper is a home run that sails well over the second fence in center field.

Final score: 22-5, Upland. A football score. Walt shakes his head. He tucks his chin into his neck and smiles. Then he jogs across the diamond with the kids to shake hands with the vanquished.

?

?

Source: http://www.phillymag.com/articles/carl-june-key-fighting-cancer/

Florida Gulf Coast University Aaron Craft school closings ariana grande gonzaga lyme disease temple university

Mobiles & Acc IPhone 4 brand new boxed (?150)

Closed Thread
Thread Tools Search this Thread
Show Printable VersionShow Printable Version Email this PageEmail this Page Search this Thread:

Advanced Search

All times are GMT. The time now is 15:46.

POSTS ON THIS FORUM ARE NOT ACTIVELY MONITORED
Click "Report Post" under any post which may breach our terms of use.

Source: http://www.sheffieldforum.co.uk/showthread.php?t=1203294&goto=newpost

Jessica Ennis Aliya Mustafina Kirk Urso London 2012 Javelin roger federer Olga Korbut Usain Bolt 2012 Olympics

Sunday, July 28, 2013

The taller the woman, the higher her cancer risk

Featured Article
Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology
Article Date: 28 Jul 2013 - 1:00 PDT

Current ratings for:
The taller the woman, the higher her cancer risk


Patient / Public:not yet rated
Healthcare Prof:not yet rated

The ability to reach items on high shelves and easily see through a crowd may no longer have the same appeal for some women. A study recently published in Cancer Epidemiology, Biomarkers & Prevention finds a link between postmenopausal women's height and cancers.

According to the study, the taller a woman's stature is, the higher her risk of cancer at a number of different sites, including breast, colon, endometrium, kidney, ovary, rectum and thyroid. Additionally, taller women have a greater risk of developing multiple myeloma and melanoma.

All of these associations did not change after adjusting for known influencers of these cancers, such as age, weight, education, smoking habits, alcohol intake and hormone therapy. The researchers say that height even had more influence over cancer risk than a common measure of obesity, body mass index (BMI).

Researchers studied 144,701 women aged 50 to 79 who participated in the Women's Health Initiative from 1993 to 1998. After a follow-up 12 years later, in total, 20,928 cancers were identified within the group.

Results showed that for every 10-centimeter increase in height (3.94 inches), there was a 13% increase in likelihood of developing cancer.

Specifically:

  • An increase in risk of 13-17% for breast, ovary, endometrium and colon cancers, as well as for melanoma, and
  • An increase in risk of 23-29% for kidney, rectum, thyroid and blood cancers.

There were 19 cancers studied in total, none of which displayed a negative association with height.

Geoffrey Kabat - senior epidemiologist in the department of epidemiology and population health at Albert Einstein College of Medicine, Yeshiva University, New York, NY - says:

"We were surprised at the number of cancer sites that were positively associated with height. In this data set, more cancers are associated with height than were associated with body mass index.

Ultimately, cancer is a result of processes having to do with growth, so it makes sense that hormones or other growth factors that influence height may also influence cancer risk."

Various studies in the past have looked at personal characteristics in relation to cancers. For example, a recent study linked height and BMI to ovarian cancer. An interesting note made by the current researchers is that both height and BMI have been increasing by about 1 cm each decade in high-income countries, potentially increasing the risk for cancer in the process.

Few previous studies have adjusted for other known influencers of cancer when researching the effect of height.

Dr. Geoffrey Kabat makes the obvious point that, unlike other risk factors such as diet and lifestyle, height is not something we can change. He adds, however:

"Although it is not a modifiable risk factor, the association of height with a number of cancer sites suggests that exposures in early life, including nutrition, play a role in influencing a person's risk of cancer."

While the researchers found an association between cancer and height, the medical evidence shows it is a complex disease that cannot be linked purely to one factor.

Written by Marie Ellis


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our cancer / oncology section for the latest news on this subject.

"Adult stature and risk of cancer at different anatomic sites in a cohort of postmenopausal women,? Geoffrey C. Kabat, et al., Cancer Epidemiology, Biomarkers & Prevention, doi: 10.1158/1055-9965.EPI-13-0305. Abstract/summary; early online release.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Ellis, Marie. "The taller the woman, the higher her cancer risk." Medical News Today. MediLexicon, Intl., 28 Jul. 2013. Web.
28 Jul. 2013. <http://www.medicalnewstoday.com/articles/264000.php>


APA

Please note: If no author information is provided, the source is cited instead.



'The taller the woman, the higher her cancer risk'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Source: http://www.medicalnewstoday.com/articles/264000.php

Green Coffee Bean Extract september 11 9/11 Memorial 911 masterchef Dictionary.com Chicago teachers strike